Selected research
Market Structure
Global Cell and Gene Therapy Enterprise Solutions Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cell and Gene Therapy Enterprise Solutions market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cell and Gene Therapy Enterprise Solutions include Thermo Fisher Scientific, Miltenyi Biotec, Bruker Spatial Biology, Charles River Laboratories, Sartorius, Revvity, Red Cross Blood Services, Proteintech Group and Promega Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Cell and Gene Therapy Enterprise Solutions market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cell and Gene Therapy Enterprise Solutions and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cell and Gene Therapy Enterprise Solutions revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Cell and Gene Therapy Enterprise Solutions market size, projected growth trends, production technologies, key applications, and end-use industries.
Cell and Gene Therapy Enterprise Solutions Segment by Company
Thermo Fisher Scientific
Miltenyi Biotec
Bruker Spatial Biology
Charles River Laboratories
Sartorius
Revvity
Red Cross Blood Services
Proteintech Group
Promega Corporation
BIOMÉRIEUX
QIAGEN
R&D Systems
Abcam
SGS
Azenta US
Vizient Inc
Cell and Gene Therapy Enterprise Solutions Segment by Type
Cell Therapy-Specific Solutions
Gene Therapy-Specific Solutions
Cell and Gene Therapy Enterprise Solutions Segment by Application
Academic/Research Lab
Biotech/Pharma Company
Clinical/Medical Institution
Cell and Gene Therapy Enterprise Solutions Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy Enterprise Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy Enterprise Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy Enterprise Solutions.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Cell and Gene Therapy Enterprise Solutions in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell and Gene Therapy Enterprise Solutions industry.
Chapter 3: Detailed analysis of Cell and Gene Therapy Enterprise Solutions companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell and Gene Therapy Enterprise Solutionsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032
Table 2. Key Players of Cell Therapy-Specific Solutions
Table 3. Key Players of Gene Therapy-Specific Solutions
Table 4. Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032
Table 5. Key Players of Academic/Research Lab
Table 6. Key Players of Biotech/Pharma Company
Table 7. Key Players of Clinical/Medical Institution
Table 8. Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 9. Global Cell and Gene Therapy Enterprise Solutions Market Size by Region (2021-2026) & (US$ Million)
Table 10. Global Cell and Gene Therapy Enterprise Solutions Market Share by Region (2021-2026)
Table 11. Global Cell and Gene Therapy Enterprise Solutions Market Size by Region (2027-2032) & (US$ Million)
Table 12. Global Cell and Gene Therapy Enterprise Solutions Market Share by Region (2027-2032)
Table 13. Cell and Gene Therapy Enterprise Solutions Industry Trends
Table 14. Cell and Gene Therapy Enterprise Solutions Industry Drivers
Table 15. Cell and Gene Therapy Enterprise Solutions Industry Opportunities and Challenges
Table 16. Cell and Gene Therapy Enterprise Solutions Industry Restraints
Table 17. Global Cell and Gene Therapy Enterprise Solutions Revenue by Company (US$ Million) & (2021-2026)
Table 18. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Company (2021-2026)
Table 19. Global Cell and Gene Therapy Enterprise Solutions Players Revenue Ranking, 2024 VS 2025 VS 2026
Table 20. Global Cell and Gene Therapy Enterprise Solutions Key Company Head Office and Area Served
Table 21. Global Cell and Gene Therapy Enterprise Solutions Company, Product Type & Application
Table 22. Global Cell and Gene Therapy Enterprise Solutions Company Establishment Date
Table 23. Global Company Market Concentration Ratio (CR5 and HHI)
Table 24. Global Cell and Gene Therapy Enterprise Solutions by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 25. Global Cell and Gene Therapy Enterprise Solutions Market Size by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 26. Global Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 27. Global Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 28. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Type (2021-2026)
Table 29. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Type (2027-2032)
Table 30. Global Cell and Gene Therapy Enterprise Solutions Market Size by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 31. Global Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 32. Global Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 33. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Application (2021-2026)
Table 34. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Application (2027-2032)
Table 35. Thermo Fisher Scientific Company Information
Table 36. Thermo Fisher Scientific Business Overview
Table 37. Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 38. Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 39. Thermo Fisher Scientific Recent Development
Table 40. Miltenyi Biotec Company Information
Table 41. Miltenyi Biotec Business Overview
Table 42. Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 43. Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 44. Miltenyi Biotec Recent Development
Table 45. Bruker Spatial Biology Company Information
Table 46. Bruker Spatial Biology Business Overview
Table 47. Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 48. Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 49. Bruker Spatial Biology Recent Development
Table 50. Charles River Laboratories Company Information
Table 51. Charles River Laboratories Business Overview
Table 52. Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 53. Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 54. Charles River Laboratories Recent Development
Table 55. Sartorius Company Information
Table 56. Sartorius Business Overview
Table 57. Sartorius Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 58. Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 59. Sartorius Recent Development
Table 60. Revvity Company Information
Table 61. Revvity Business Overview
Table 62. Revvity Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 63. Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 64. Revvity Recent Development
Table 65. Red Cross Blood Services Company Information
Table 66. Red Cross Blood Services Business Overview
Table 67. Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 68. Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 69. Red Cross Blood Services Recent Development
Table 70. Proteintech Group Company Information
Table 71. Proteintech Group Business Overview
Table 72. Proteintech Group Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 73. Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 74. Proteintech Group Recent Development
Table 75. Promega Corporation Company Information
Table 76. Promega Corporation Business Overview
Table 77. Promega Corporation Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 78. Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 79. Promega Corporation Recent Development
Table 80. BIOMÉRIEUX Company Information
Table 81. BIOMÉRIEUX Business Overview
Table 82. BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 83. BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 84. BIOMÉRIEUX Recent Development
Table 85. QIAGEN Company Information
Table 86. QIAGEN Business Overview
Table 87. QIAGEN Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 88. QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 89. QIAGEN Recent Development
Table 90. R&D Systems Company Information
Table 91. R&D Systems Business Overview
Table 92. R&D Systems Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 93. R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 94. R&D Systems Recent Development
Table 95. Abcam Company Information
Table 96. Abcam Business Overview
Table 97. Abcam Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 98. Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 99. Abcam Recent Development
Table 100. SGS Company Information
Table 101. SGS Business Overview
Table 102. SGS Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 103. SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 104. SGS Recent Development
Table 105. Azenta US Company Information
Table 106. Azenta US Business Overview
Table 107. Azenta US Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 108. Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 109. Azenta US Recent Development
Table 110. Vizient Inc Company Information
Table 111. Vizient Inc Business Overview
Table 112. Vizient Inc Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 113. Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio
Table 114. Vizient Inc Recent Development
Table 115. North America Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 116. North America Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 117. North America Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 118. North America Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 119. North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 120. North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
Table 121. North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
Table 122. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 123. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 124. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 125. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 126. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 127. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
Table 128. Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
Table 129. China Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 130. China Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 131. China Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 132. China Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 133. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 134. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 135. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 136. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 137. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 138. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
Table 139. Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
Table 140. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026) & (US$ Million)
Table 141. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032) & (US$ Million)
Table 142. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026) & (US$ Million)
Table 143. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032) & (US$ Million)
Table 144. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 145. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
Table 146. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
Table 147. Research Programs/Design for This Report
Table 148. Authors List of This Report
Table 149. Secondary Sources
Table 150. Primary Sources
List of Figures
Figure 1. Cell and Gene Therapy Enterprise Solutions Product Image
Figure 2. Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million)
Figure 3. Global Cell and Gene Therapy Enterprise Solutions Market Share by Type: 2025 VS 2032
Figure 4. Cell Therapy-Specific Solutions Image
Figure 5. Gene Therapy-Specific Solutions Image
Figure 6. Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million)
Figure 7. Global Cell and Gene Therapy Enterprise Solutions Market Share by Application: 2025 VS 2032
Figure 8. Academic/Research Lab Image
Figure 9. Biotech/Pharma Company Image
Figure 10. Clinical/Medical Institution Image
Figure 11. Global Cell and Gene Therapy Enterprise Solutions Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 12. Global Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 13. Global Cell and Gene Therapy Enterprise Solutions Market Share by Region: 2025 VS 2032
Figure 14. Years Considered
Figure 15. Global Cell and Gene Therapy Enterprise Solutions Market Share by Players in 2025
Figure 16. Global Top 5 and 10 Cell and Gene Therapy Enterprise Solutions Players Market Share by Revenue in 2025
Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 18. Global Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Type (2021-2032)
Figure 20. Global Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 21. Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Application (2021-2032)
Figure 22. North America Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 23. North America Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
Figure 24. North America Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
Figure 25. North America Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
Figure 26. United States Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 27. Canada Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 28. Mexico Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 29. Europe Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 30. Europe Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
Figure 31. Europe Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
Figure 32. Europe Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
Figure 33. Germany Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 34. France Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 35. U.K. Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 36. Italy Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 37. Russia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 38. Nordic Countries Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 39. China Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 40. China Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
Figure 41. China Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
Figure 42. Asia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 43. Asia Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
Figure 44. Asia Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
Figure 45. Asia Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
Figure 46. Japan Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 47. South Korea Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 48. Taiwan Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 49. Southeast Asia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 50. India Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 51. Australia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 52. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 53. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
Figure 54. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
Figure 55. South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
Figure 56. Brazil Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 57. South Africa Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 58. Saudi Arabia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 59. Turkey Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 60. Argentina Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 61. UAE Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 62. Egypt Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 63. Chile Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million)
Figure 64. Research Process
Figure 65. Key Executives Interviewed
Scope & coverage.
Types
- Cell Therapy-Specific Solutions
- Gene Therapy-Specific Solutions
Applications
- Academic/Research Lab
- Biotech/Pharma Company
- Clinical/Medical Institution
Companies covered
- Thermo Fisher Scientific
- Miltenyi Biotec
- Bruker Spatial Biology
- Charles River Laboratories
- Sartorius
- Revvity
- Red Cross Blood Services
- Proteintech Group
- Promega Corporation
- BIOMÉRIEUX
- QIAGEN
- R&D Systems
- Abcam
- SGS
- Azenta US
- Vizient Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Cell Therapy-Specific Solutions
- 1.2.3 Gene Therapy-Specific Solutions
- 1.3 Market Analysis by Application
- 1.3.1 Global Cell and Gene Therapy Enterprise Solutions Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Academic/Research Lab
- 1.3.3 Biotech/Pharma Company
- 1.3.4 Clinical/Medical Institution
- 1.4 Global Market Growth Prospects
- 1.5 Global Cell and Gene Therapy Enterprise Solutions Growth Trends by Region
- 1.5.1 Global Cell and Gene Therapy Enterprise Solutions Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Cell and Gene Therapy Enterprise Solutions Market Size by Region (2021-2026)
- 1.5.3 Cell and Gene Therapy Enterprise Solutions Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Cell and Gene Therapy Enterprise Solutions Market Dynamics
- 2.1 Cell and Gene Therapy Enterprise Solutions Industry Trends
- 2.2 Cell and Gene Therapy Enterprise Solutions Industry Drivers
- 2.3 Cell and Gene Therapy Enterprise Solutions Industry Opportunities and Challenges
- 2.4 Cell and Gene Therapy Enterprise Solutions Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Cell and Gene Therapy Enterprise Solutions Revenue by Company (2021-2026)
- 3.2 Global Cell and Gene Therapy Enterprise Solutions Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Cell and Gene Therapy Enterprise Solutions Key Company Head office and Area Served
- 3.4 Global Cell and Gene Therapy Enterprise Solutions Company, Product Type & Application
- 3.5 Global Cell and Gene Therapy Enterprise Solutions Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Cell and Gene Therapy Enterprise Solutions Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Cell and Gene Therapy Enterprise Solutions Players Market Share by Revenue in 2025
- 3.6.3 2025 Cell and Gene Therapy Enterprise Solutions Tier 1, Tier 2, and Tier 3
4 Cell and Gene Therapy Enterprise Solutions Market by Type
- 4.1 Global Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2032)
- 4.3 Global Cell and Gene Therapy Enterprise Solutions Market Size Share by Type (2021-2032)
5 Cell and Gene Therapy Enterprise Solutions Market by Application
- 5.1 Global Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2032)
- 5.3 Global Cell and Gene Therapy Enterprise Solutions Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Thermo Fisher Scientific
- 6.1.1 Thermo Fisher Scientific Company Information
- 6.1.2 Thermo Fisher Scientific Business Overview
- 6.1.3 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.1.5 Thermo Fisher Scientific Recent Developments
- 6.2 Miltenyi Biotec
- 6.2.1 Miltenyi Biotec Company Information
- 6.2.2 Miltenyi Biotec Business Overview
- 6.2.3 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.2.5 Miltenyi Biotec Recent Developments
- 6.3 Bruker Spatial Biology
- 6.3.1 Bruker Spatial Biology Company Information
- 6.3.2 Bruker Spatial Biology Business Overview
- 6.3.3 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.3.5 Bruker Spatial Biology Recent Developments
- 6.4 Charles River Laboratories
- 6.4.1 Charles River Laboratories Company Information
- 6.4.2 Charles River Laboratories Business Overview
- 6.4.3 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.4.5 Charles River Laboratories Recent Developments
- 6.5 Sartorius
- 6.5.1 Sartorius Company Information
- 6.5.2 Sartorius Business Overview
- 6.5.3 Sartorius Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.5.5 Sartorius Recent Developments
- 6.6 Revvity
- 6.6.1 Revvity Company Information
- 6.6.2 Revvity Business Overview
- 6.6.3 Revvity Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.6.5 Revvity Recent Developments
- 6.7 Red Cross Blood Services
- 6.7.1 Red Cross Blood Services Company Information
- 6.7.2 Red Cross Blood Services Business Overview
- 6.7.3 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.7.5 Red Cross Blood Services Recent Developments
- 6.8 Proteintech Group
- 6.8.1 Proteintech Group Company Information
- 6.8.2 Proteintech Group Business Overview
- 6.8.3 Proteintech Group Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.8.5 Proteintech Group Recent Developments
- 6.9 Promega Corporation
- 6.9.1 Promega Corporation Company Information
- 6.9.2 Promega Corporation Business Overview
- 6.9.3 Promega Corporation Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.9.5 Promega Corporation Recent Developments
- 6.10 BIOMÉRIEUX
- 6.10.1 BIOMÉRIEUX Company Information
- 6.10.2 BIOMÉRIEUX Business Overview
- 6.10.3 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.10.5 BIOMÉRIEUX Recent Developments
- 6.11 QIAGEN
- 6.11.1 QIAGEN Company Information
- 6.11.2 QIAGEN Business Overview
- 6.11.3 QIAGEN Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.11.5 QIAGEN Recent Developments
- 6.12 R&D Systems
- 6.12.1 R&D Systems Company Information
- 6.12.2 R&D Systems Business Overview
- 6.12.3 R&D Systems Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.12.5 R&D Systems Recent Developments
- 6.13 Abcam
- 6.13.1 Abcam Company Information
- 6.13.2 Abcam Business Overview
- 6.13.3 Abcam Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.13.5 Abcam Recent Developments
- 6.14 SGS
- 6.14.1 SGS Company Information
- 6.14.2 SGS Business Overview
- 6.14.3 SGS Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.14.5 SGS Recent Developments
- 6.15 Azenta US
- 6.15.1 Azenta US Company Information
- 6.15.2 Azenta US Business Overview
- 6.15.3 Azenta US Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.15.5 Azenta US Recent Developments
- 6.16 Vizient Inc
- 6.16.1 Vizient Inc Company Information
- 6.16.2 Vizient Inc Business Overview
- 6.16.3 Vizient Inc Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 6.16.5 Vizient Inc Recent Developments
7 North America
- 7.1 North America Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 7.2 North America Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 7.2.1 North America Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026)
- 7.2.2 North America Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032)
- 7.2.3 North America Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
- 7.3 North America Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 7.3.1 North America Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026)
- 7.3.2 North America Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032)
- 7.3.3 North America Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
- 7.4 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country
- 7.4.1 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 7.4.3 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 7.4.4 North America Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 8.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 8.2.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026)
- 8.2.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032)
- 8.2.3 Europe Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
- 8.3 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 8.3.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026)
- 8.3.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032)
- 8.3.3 Europe Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
- 8.4 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country
- 8.4.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 8.4.3 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 8.4.4 Europe Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 9.2 China Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 9.2.1 China Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026)
- 9.2.2 China Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032)
- 9.2.3 China Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
- 9.3 China Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 9.3.1 China Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026)
- 9.3.2 China Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032)
- 9.3.3 China Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 10.2 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 10.2.1 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026)
- 10.2.2 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032)
- 10.2.3 Asia Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
- 10.3 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 10.3.1 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026)
- 10.3.2 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032)
- 10.3.3 Asia Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
- 10.4 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country
- 10.4.1 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 10.4.3 Asia Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 10.4.4 Asia Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Type
- 11.2.1 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Application
- 11.3.1 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country
- 11.4.1 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst